Journey Medical Quick Ratio (DERM) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Journey Medical Corp  (NASDAQ: DERM)

Journey Medical's Quick Ratio

DERM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.56 below Journey Medical Corp average.

Within Major Pharmaceutical Preparations industry 385 other companies have achieved higher Quick Ratio than Journey Medical in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1853 to 2361.

Explain Quick Ratio?
How much Cash & cash equivalents DERM´s has?
What are DERM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DERM Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 13.07 % -5.95 % 6.44 % 19.15 % 18.55 %
Y / Y Cash & cash equivalent Change 26.36 % 29.18 % 18.64 % 11.07 % -15.13 %
Quick Ratio MRQ 0.56 0.72 0.64 0.63 0.5
DERM's Total Ranking # 2361 # 1853 # 2080 # 2095 # 1828
Seq. Current Liabilities Change 20.99 % 1.04 % -5.72 % -1.89 % 0.64 %
Seq. Cash & cash equivalent Change -5.79 % 12.99 % -3.44 % 22.94 % -3.69 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 386
Healthcare Sector # 722
Overall Market # 2361


Quick Ratio Statistics
High Average Low
24.15 5.37 0.12
(Jun 30 2017)   (Jun 30 2023)




Financial Statements
Journey Medical's Current Liabilities $ 46 Millions Visit DERM's Balance sheet
Journey Medical's Cash & cash equivalent $ 26 Millions Visit DERM's Balance sheet
Source of DERM's Sales Visit DERM's Sales by Geography


Cumulative Journey Medical's Quick Ratio

DERM's Quick Ratio for the trailling 12 Months

DERM Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 7.74 % 8.81 % 11.49 % 4.93 % -6.95 %
Y / Y Cash & cash equivalent TTM Growth 21.12 % 10.03 % -0.37 % -11.5 % -16 %
Quick Ratio TTM 0.63 0.62 0.57 0.56 0.56
Total Ranking TTM # 4080 # 4035 # 2982 # 3358 # 2754
Seq. Current Liabilities TTM Growth 3.4 % -1.52 % 1.46 % 4.28 % 4.43 %
Seq. Cash & cash equivalent TTM Growth 5.54 % 6.8 % 4.37 % 2.96 % -4.12 %

Quick ratio ranking by company, industry and sector >> Back to DERM Financial Strength Comparisons >> Go to Compare DERM Quick Ratio to its Competitors

  News about Journey Medical Corp Quick Ratio

Journey Medical's $20 Million Credit Facility Expands Horizons, Paves the Way for DFD-29's Revolutionary Dermatology Breakthrough

Journey Medical Corporation Secures Credit Facility from SWK Holdings, Opening Doors for Future Growth and Innovation
In an exciting development for Journey Medical Corporation, the company has successfully secured a credit facility with SWK Holdings for up to $20 million. This newfound financial support not only strengthens Journey s position in the market but also propels its potential launch of DFD-29, the highly anticipated product in its pipeline.
With the additional capital injected into its general corporate purposes, Journey Medical Corporation can now accelerate its growth strategies, invest in innovative research and development initiatives, and expand its reach to cater to a wider customer base. This fresh infusion of funds allows the company to boldly venture into unexplored territories and forge ahead on its mission to transform the dermatology sector.

On the trailing twelve months basis DERM Cash & cash equivalent grew by 26.36 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Journey Medical's Quick Ratio to 0.63, Quick Ratio remained below DERM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Journey Medical. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 4035 to 4080.

Explain Quick Ratio?
How much Cash & cash equivalents DERM´s has?
What are DERM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 905
Within the Market # 4080


trailing twelve months Quick Ratio Statistics
High Average Low
14.08 4.44 0.32
(Jun 30 2017)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions
Arcutis Biotherapeutics Inc   1.49 $ 238.552  Millions$ 160.340  Millions
Mirum Pharmaceuticals Inc   1.48 $ 330.728  Millions$ 222.788  Millions
Regeneron Pharmaceuticals Inc   1.45 $ 7,994.600  Millions$ 5,530.600  Millions
Imunon Inc   1.44 $ 6.900  Millions$ 4.779  Millions
Zai Lab Limited  1.44 $ 617.522  Millions$ 428.584  Millions
Mannkind Corporation  1.44 $ 205.271  Millions$ 142.898  Millions
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions
Avenue Therapeutics Inc   1.38 $ 1.942  Millions$ 1.407  Millions
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions
Ani Pharmaceuticals Inc  1.27 $ 360.212  Millions$ 283.655  Millions
Pmgc Holdings Inc   1.25 $ 19.126  Millions$ 15.329  Millions
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions
Actuate Therapeutics Inc   1.16 $ 4.426  Millions$ 3.805  Millions
Apimeds Pharmaceuticals US, Inc.  1.16 $ 8.278  Millions$ 7.166  Millions
Emergent Biosolutions Inc   1.14 $ 139.700  Millions$ 122.800  Millions
Turn Therapeutics Inc   1.14 $ 9.958  Millions$ 8.764  Millions
Ionis Pharmaceuticals Inc   1.11 $ 350.065  Millions$ 315.638  Millions
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions

Date modified: 2026-09-26T07:41:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.